605199 Stock Overview
Hainan Huluwa Pharmaceutical Group Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Hainan Huluwa Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥17.90 |
| 52 Week High | CN¥25.16 |
| 52 Week Low | CN¥9.09 |
| Beta | 0.67 |
| 1 Month Change | 41.73% |
| 3 Month Change | 63.77% |
| 1 Year Change | 18.07% |
| 3 Year Change | -25.10% |
| 5 Year Change | n/a |
| Change since IPO | 139.63% |
Recent News & Updates
Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) 43% Share Price Surge Not Quite Adding Up
Nov 29
We Think That There Are Issues Underlying Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Earnings
Nov 06Recent updates
Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) 43% Share Price Surge Not Quite Adding Up
Nov 29We Think That There Are Issues Underlying Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Earnings
Nov 06Here's Why Hainan Huluwa Pharmaceutical Group (SHSE:605199) Has A Meaningful Debt Burden
Oct 23Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Shares Climb 27% But Its Business Is Yet to Catch Up
Sep 25There's Reason For Concern Over Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Massive 27% Price Jump
Sep 25Risks To Shareholder Returns Are Elevated At These Prices For Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199)
Jun 07Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings
May 03Shareholder Returns
| 605199 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -7.7% | -1.9% | -1.2% |
| 1Y | 18.1% | -1.8% | 11.8% |
Return vs Industry: 605199 exceeded the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 605199 exceeded the CN Market which returned 11.8% over the past year.
Price Volatility
| 605199 volatility | |
|---|---|
| 605199 Average Weekly Movement | 12.0% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 605199's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 605199's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2,468 | Jinping Liu | www.huluwayaoye.com |
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other therapeutic in China. It offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products.
Hainan Huluwa Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 605199 fundamental statistics | |
|---|---|
| Market cap | CN¥7.16b |
| Earnings (TTM) | CN¥112.88m |
| Revenue (TTM) | CN¥1.82b |
63.4x
P/E Ratio3.9x
P/S RatioIs 605199 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 605199 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.82b |
| Cost of Revenue | CN¥830.01m |
| Gross Profit | CN¥990.98m |
| Other Expenses | CN¥878.10m |
| Earnings | CN¥112.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 54.42% |
| Net Profit Margin | 6.20% |
| Debt/Equity Ratio | 110.4% |
How did 605199 perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield43%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 13:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hainan Huluwa Pharmaceutical Group Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|